MX351074B - Vacunas contra clostridium difficile que comprenden toxinas recombinantes. - Google Patents

Vacunas contra clostridium difficile que comprenden toxinas recombinantes.

Info

Publication number
MX351074B
MX351074B MX2014009106A MX2014009106A MX351074B MX 351074 B MX351074 B MX 351074B MX 2014009106 A MX2014009106 A MX 2014009106A MX 2014009106 A MX2014009106 A MX 2014009106A MX 351074 B MX351074 B MX 351074B
Authority
MX
Mexico
Prior art keywords
toxin
recombinant
difficile
toxins
cdta
Prior art date
Application number
MX2014009106A
Other languages
English (en)
Spanish (es)
Other versions
MX2014009106A (es
Inventor
Paulus Jacobus Antonius Sondermeijer
Jon Henry Heinrichs
Jean Luc Bodmer
Susan Lynn Secore
Aaron Rudy Goerke
Aguilar Ivette Caro
Marie Pierre Gentile
Melanie S Horton
Matthew Ryan Miezeiewski
Julie M Skinner
Shyamsundar Subramanian
Liefkens Karin Huberdina Antonia Van Der Heijden
Su Wang
Jinfu Xie
Rachel Flora Xoconostle
Julie K Zorman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2014009106A publication Critical patent/MX2014009106A/es
Publication of MX351074B publication Critical patent/MX351074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2014009106A 2012-01-27 2013-01-25 Vacunas contra clostridium difficile que comprenden toxinas recombinantes. MX351074B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261591631P 2012-01-27 2012-01-27
US201261596419P 2012-02-08 2012-02-08
US201261703754P 2012-09-20 2012-09-20
PCT/US2013/023189 WO2013112867A1 (en) 2012-01-27 2013-01-25 Vaccines against clostridium difficile comprising recombinant toxins

Publications (2)

Publication Number Publication Date
MX2014009106A MX2014009106A (es) 2014-11-10
MX351074B true MX351074B (es) 2017-09-28

Family

ID=48873956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009106A MX351074B (es) 2012-01-27 2013-01-25 Vacunas contra clostridium difficile que comprenden toxinas recombinantes.

Country Status (14)

Country Link
US (1) US9388394B2 (cg-RX-API-DMAC7.html)
EP (1) EP2807186A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015506948A (cg-RX-API-DMAC7.html)
KR (1) KR20140117433A (cg-RX-API-DMAC7.html)
CN (1) CN104039816B (cg-RX-API-DMAC7.html)
AR (1) AR089797A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013211973B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014018432A8 (cg-RX-API-DMAC7.html)
CA (1) CA2856443A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04187A (cg-RX-API-DMAC7.html)
MX (1) MX351074B (cg-RX-API-DMAC7.html)
RU (1) RU2014134365A (cg-RX-API-DMAC7.html)
TW (1) TW201335178A (cg-RX-API-DMAC7.html)
WO (1) WO2013112867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR112014013876A2 (pt) * 2011-12-08 2019-09-24 Novartis Ag vacina à base de toxina de clostridium difficile
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP2988778A4 (en) * 2013-04-22 2016-12-14 Board Of Regents Of The Univ Of Oklahoma CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
AU2014277981B2 (en) 2013-06-14 2019-06-20 Sanofi Pasteur Inc. Compositions and methods of immunizing against C. difficile
PL3160500T3 (pl) * 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
JP2017212882A (ja) * 2014-10-10 2017-12-07 学校法人 名城大学 アセチルエステラーゼ及びその利用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180011784A (ko) 2015-05-15 2018-02-02 사노피 파스퇴르 인코포레이티드 클로스트리듐 디피실에 대한 면역화 방법
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
KR20180114891A (ko) 2016-03-02 2018-10-19 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소를 포함하는 조성물
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
CA3056090A1 (en) * 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
JP7349366B2 (ja) * 2017-06-09 2023-09-22 ヒプラ シエンティフィック エセ．エレ．ウ． クロストリジウム類毒素を含むワクチン
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
US20200123210A1 (en) * 2018-10-17 2020-04-23 Eternity Biomedical Laboratories, Inc. Immunogenic preparations and methods against clostridium difficile infection
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN118613492A (zh) * 2022-01-30 2024-09-06 西湖大学 Tfpi结合多肽及其用途
JP2023134918A (ja) * 2022-03-15 2023-09-28 株式会社荏原製作所 研磨方法および研磨装置
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE69829400T2 (de) 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US7713535B2 (en) 2003-12-08 2010-05-11 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
ES2533492T3 (es) 2004-02-06 2015-04-10 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
KR101149687B1 (ko) * 2006-03-30 2012-05-25 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
EP2396652B1 (en) * 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
AU2010215275B2 (en) * 2009-02-20 2016-03-31 Micropharm Limited Antibodies to Clostridium difficile toxins
KR20120061053A (ko) 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(ｉＰＳ) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
CA2782406A1 (en) 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
BR112013027229B1 (pt) * 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante

Also Published As

Publication number Publication date
CN104039816B (zh) 2018-02-09
CN104039816A (zh) 2014-09-10
IN2014CN04187A (cg-RX-API-DMAC7.html) 2015-07-17
WO2013112867A1 (en) 2013-08-01
MX2014009106A (es) 2014-11-10
US20150044250A1 (en) 2015-02-12
TW201335178A (zh) 2013-09-01
EP2807186A4 (en) 2016-01-27
BR112014018432A8 (pt) 2017-07-11
AU2013211973B2 (en) 2017-10-12
AR089797A1 (es) 2014-09-17
AU2013211973A1 (en) 2014-06-12
JP2015506948A (ja) 2015-03-05
RU2014134365A (ru) 2016-03-20
KR20140117433A (ko) 2014-10-07
JP2017141226A (ja) 2017-08-17
CA2856443A1 (en) 2013-08-01
BR112014018432A2 (cg-RX-API-DMAC7.html) 2017-06-20
US9388394B2 (en) 2016-07-12
EP2807186A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
EP4241851A3 (en) Immunogenic compositions
MX2024013161A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs)
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112021025172A2 (pt) Proteínas de fusão para vacinas de tuberculose
MX373395B (es) Vacuna de haemophilus parasuis para serovar tipo cuatro.
MX2015017257A (es) Composiciones y metodos de inmunizar contra clostridium difficile.
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
MX2016002823A (es) Metodos y composiciones para vacunas vectorizadas virales.
MX2017014666A (es) Metodos de inmunización contra clostridium difficile.
WO2013084070A3 (en) Salmonella vaccine proteins
MX2015013808A (es) Vacuna contra garrapatas rhipicephalus.
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
WO2021019235A3 (en) Hantavirus antigenic composition
MX2017016858A (es) Composiciones inmunogenicas.
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
WO2020227605A3 (en) Dna encoded il-36 gamma as an adjuvant

Legal Events

Date Code Title Description
FG Grant or registration